Key facts
- This page summarizes Elaine K. Sorg's Form 4 filing for AbbVie Inc. (ABBV).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Apr 2023, 17:00.
Elaine K. Sorg - 25 Apr 2023 Form 4 Insider Report for AbbVie Inc. (ABBV)
- Reporting relationship
- SVP, US COMMERCIAL OPERATIONS
- Issuer ticker
- ABBV
- Reported as of
- 25 Apr 2023
- Net transaction value
- -$1,011,450
- SEC form
- 4
- Accepted by SEC
- 27 Apr 2023, 17:00:18 UTC
- Prior SEC filing
- 19 Apr 2023
- Next SEC filing
- 19 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- Steven L. Scrogham, attorney-in-fact for Elaine K. Sorg
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Elaine K. Sorg filed Form 4 for AbbVie Inc. (ABBV) on 27 Apr 2023.
Change
- Previous filing in this sequence was filed on 19 Apr 2023.
- Current net transaction value: -$1,011,450.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABBV
transaction
Common Stock, $0.01 par value
Options Exercise
- Transaction value
- $886,030
- Shares
- +6,130
- Change %
- +17%
- Price
- $144.54
- Shares after
- 41,460
- Date
- 25 Apr 2023
- Ownership
- Direct
ABBV
transaction
Common Stock, $0.01 par value
Sale
- Transaction value
- $1,011,450
- Shares
- -6,130
- Change %
- -15%
- Price
- $165.00
- Shares after
- 35,330
- Date
- 25 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABBV
transaction
Derivative
Option (Right to Buy)
Options Exercise
- Transaction value
- $886,030
- Shares
- -6,130
- Change %
- -33%
- Price
- $144.54
- Shares after
- 12,258
- Date
- 25 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,130
- Exercise price
- $144.54
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.00 to $165.03, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
SEC remarks
The option exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 14, 2023.